News About: Pharm. Industry
Cash dividends at KOSPI pharmaceutical firms top 15%
Cash dividends paid out by KOSPI-listed pharmaceutical companies posted about 15 percent on average in 2010, according to Yakup Shinmoon (www.yakup.com).
A total of 23 KOSPI-listed drug companies paid cash dividend...
JW completes phase 3 study for biological response modifier
JW Pharmaceutical said Thursday it has completed its local Phase III study for Actemra (tocilizumab), an investigational biological therapy for rheumatoid arthritis.
According to the company, the local Phase III st...
Reliable CROs are vital to Korean drugmakers
Local pharmaceutical companies are expanding their businesses abroad to enlarge and diversify their customer base while creating opportunities to improve their products through cooperation with foreign firms.
"Loca...
Green Cross to conduct clinical trial of anti-anemic agent
Green Cross Corporation said Tuesday it will carry out Phase 1 trial for GC1113, a generic version of Amgen’s Epogen.
Co-developed by Genexine, GC1113 is a recombinant fusion protein comprising a human erythropoiet...
A good news for Propecia users
Propecia (finasteride) is very effective in stopping baldness in men and is unlinked to male sexual dysfunction, a local clinical study showed.
The clinical trial of 24 men with baldness showed that 22 showed no se...
Government urged to increase wholesaler margin
So far, domestic wholesalers have seen their margins falling as multinational drug manufactures and Zuellig Pharma Korea have acknowledged wholesaler margin at 5 to 6.5 percent at most, which has affected their bottom...
No casualties reported in Japanese pharmaceutical firms
The earthquake and tsunami that hit Japan, Friday, caused no casualties in Japanese pharmaceutical companies.
The majority of Japanese drugmakers here, including Daiichi-Kirin, Otsuka Korea and Astellas Korea, said...
Pharmaceutical export is unlikely to respond to Japanese earthquake
Korea will not benefit from Japan’s earthquake, while shares of domestic drugmakers such as CJ Cheil Jedang and Jeil Pharmaceutical are forecast to see gains, as growing demand for vaccines and antibiotics are expecte...
Ilyang to operate flu vaccine plant
Ilyang Pharmaceutical Co. says it will complete its vaccine plant for influenza with an annual egg-based production capacity of 60 million doses of flu vaccine in Jecheon, North Chungcheong on April 11, one year after...
Fiercer generic battle to be seen
With many global makers' blockbuster products coming off patent until 2014, the race for the generic drug market is set to be in full force in the years to come.
The original brands to expire in the first half of t...
